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Background: The current radiation threat from the Fukushima power plant accident has prompted 
rethinking of the contingency plan for prophylaxis and treatment of the acute radiation syndrome 
(ARS). The well-documented effect of the growth factors (granulocyte colony-stimulating factor 
[G-CSF] and granulocyte-macrophage colony-stimulating factor [GM-CSF]) in acute radia-
tion injury has become standard treatment for ARS in the United States, based on the fact that 
growth factors increase number and functions of both macrophages and granulocytes.
Methods: Review of the current literature.
Results: The lungs have their own host defense system, based on alveolar macrophages. After 
radiation exposure to the lungs, resting macrophages can no longer be transformed, not even 
during systemic administration of growth factors because G-CSF/GM-CSF does not penetrate 
the alveoli. Under normal circumstances, locally-produced GM-CSF receptors transform 
resting macrophages into fully immunocompetent dendritic cells in the sealed-off pulmonary 
  compartment. However, GM-CSF is not expressed in radiation injured tissue due to deferves-
cence of the macrophages. In order to maintain the macrophage’s important role in host defense 
after radiation exposure, it is hypothesized that it is necessary to administer the drug exogenously 
in order to uphold the barrier against exogenous and endogenous infections and possibly prevent 
the potentially lethal systemic infection, which is the main cause of death in ARS.
Recommendation: Preemptive treatment should be initiated after suspected exposure of 
a radiation dose of at least ∼2 Gy by prompt dosing of 250–400 µg GM-CSF/m2 or 5 µg/kg 
G-CSF administered systemically and concomitant inhalation of GM-CSF ∼ 300 mcg per day 
for at least 14–21 days.
Conclusion: The present United States standard for prevention and treatment of ARS stan-
dard intervention should consequently be modified into the combined systemic administration 
of growth factors and inhaled GM-CSF to ensure the sustained systemic and pulmonary host 
defense and thus prevent pulmonary dysfunction.
Keywords: inhaled and systemically administered GM-CSF, ARS, host defense, orchestration 
of pulmonary host response
Introduction
The present review is based on reported experiences from inadvertent radiation expo-
sure during acute radiation accidents and on a literature search taking into account the 
newest documentation about the benefit of administering growth factors (granulocyte 
colony-stimulating factor [G-CSF]/granulocyte-macrophage colony-stimulating factor 
[GM-CSF]). Exposure with a high dose radiation induces the so-called acute radiation 
syndrome (ARS) followed by severe injury to stem cells, organs, and tissues.1 The 
seriously-affected patient with bone marrow aplasia will experience reduced defense 
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against exogenous and endogenous factors, such as infection 
and inflammation, and consequently suffer from invasive 
infection and organ dysfunction, which may be relieved 
by allogenous hematopoietic stem cell transplantation 
(HSCT),2–4 although treatment results are not encouraging. 
In extreme cases, the radiation injury may be fatal for the 
exposed person.4–7 All organs may be affected and damaged. 
However, airways are potentially exposed to a “double hit 
injury” in that the lungs receive exposure to gamma irra-
diation along with the rest of the body as well as potential 
radiation from inhaled radioactive dust particles.
ARS
ARS is a combination of acute injury manifestations that 
occur after a sufficiently large portion of the body is exposed 
to a high dose of ionizing radiation. ARS is defined as the 
signs and symptoms that occur after a whole-body or sig-
nificant partial-body (60%) exposure of .1 Gy total dose, 
delivered acutely at a relatively high-dose rate. Such irradia-
tion injury initially affects all organs to some extent, but the 
timing and extent of the injury manifestations depend upon 
the type, rate, and dose of radiation received.4 The percent-
age of the body that is injured, the dose homogeneity, and 
the intrinsic radiosensitivity of the exposed individual also 
influence manifestations. Different ranges of whole-body 
doses produce different manifestations of injury. The three 
main ranges that produce the most characteristic manifesta-
tions are referred to as the hematological, gastrointestinal, 
and neurovascular syndromes. These syndromes are, as a 
rule, produced only with whole-body or near whole-body 
irradiation by photon or mixed photon/neutron radiation. 
High-dose injuries to smaller percentages of the body produce 
local injury effects, but may not cause ARS.4,5
Radiation damage primarily affects proliferating cells 
because they are the most sensitive to acute effects.2 The 
tissues therefore have different sensitivity thresholds for 
the release of clinical symptoms after radiation. Bone mar-
row and the intestines have a low threshold caused by fast 
cellular turnover, whereas muscles and brain cells multiply 
slowly and are more resistant to radiation. The clinical 
components of ARS include several subsyndromes, each 
with a specific trigger sensitivity threshold for the release 
of clinical symptoms like the hematologic, gastrointestinal, 
cerebrovascular, and multiorgan/pulmonary dysfunction 
syndromes (Table 1).
Each syndrome can be divided into four phases: pro-
dromal, latent, manifest illness, and recovery or death.2–4,8–10 
The time course and severity of clinical signs and symptoms 
for ARS subsyndromes at different dose ranges are reviewed 
in Table 2.
The most sensitive cells to acute radiation effect are in 
bone marrow. However, an overlooked fact is that there are 
other important replicative cells, namely the fixed tissue 
macrophages in tissue and vital organs. Depending on the 
absorbed radioactive dose, symptoms appear within hours to 
weeks, following a predictable clinical course. The prodromal 
phase of ARS usually occurs in the first 48 hours, but may 
develop up to 6 days after exposure.2 The latent phase is a 
short period characterized by improvement of symptoms as 
the person appears to have recovered. Unfortunately, this 
effect is transient, lasting for several days to a month.
Symptoms of manifest illness then appear and may last 
for weeks. This stage is characterized by intense immuno-
suppression and is the most difficult to manage. If a person 
survives this stage, recovery is likely. Individuals exposed 
to a supralethal dose of radiation deteriorate over a period 
of hours, resulting in early death.4,5
Symptoms of acute, high-dose radiation are dependent 
on the absorbed dose. They may appear within hours to days 
and follow a somewhat predictable course.12 Early symptoms 
resulting from an acute whole-body exposure constitute the 
prodromal radiation syndrome. Virtually all individuals 
receiving a dose of 10–20 Gy develop prodromal signs and 
symptoms within 1–72 hours after exposure.2,4,5 The initial 
clinical picture is most often dominated by gastrointestinal 
signs and symptoms (Table 2) primarily resulting from 
central nervous system manifestations due to the location of 
the control center of anorexia, nausea, and vomiting in the 
brain. Central nervous system dysfunction may be evident 
early on by changes in the electroencephalography, even at 
much lower doses. In later phases, the symptoms gradually 
Table 1 Overview of acute radiation syndrome (ARS) following 
exposure to radiation2
Dose response in respect to radiation injury
  –   ARS is the host response against exogenous radiation injury, which 
may be fatal for the exposed person
Organ dysfunction in ARS
  –   Even at low irradiation doses bone marrow stem cells will be 
affected, and thus neutrophils, monocytes, and erythrocytes
  –   The function of organ fixed macrophages will also be harmed, which 
in turn will reduce outermost host defense barrier
Prophylactic treatment of ARS
  –   Conventional treatment and supportive care in ARS have limited 
effect on recovery from elevated levels of radiation exposure
  –   The only effective intervention to date in reducing the mortality in 
ARS is treatment with growth factors: granulocyte colony-stimulating 
factor and granulocyte-macrophage colony-stimulating factor, which 
have a documented positive effect on recovery from ARS8,9
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merge into loss of consciousness, hypotension, and death 
  (components of the cerebrovascular syndrome that is char-
acterized by neurologic failure and cardiovascular collapse) 
before toxicity to other organ systems (such as the gastroin-
testinal and hematologic systems) can develop.
Death occurs within a few days after exposure to 10–20 Gy, 
in absence of treatment.4,5 A rapid, severe prodromal response 
is the harbinger of a poor clinical outcome that is complicated 
by severe leukoneutropenia, thrombocytopenia, and anemia 
with reticulocytopenia, accompanied by hemorrhage, infec-
tion, and death. At lower doses (2–10 Gy), it is difficult to 
establish a prognosis based on the prodromal phase. The 
prodromal phase is followed by a phase of manifest illness 
where syndromes specific to various organ systems emerge. 
Four major organ subsystems are known to be of critical 
significance in the development of ARS: the gastrointes-
tinal system, neurovascular system, hematologic system, 
and pulmonary system. Evaluation of system-specific signs 
and symptoms is required for triage of victims, selection of 
therapy, and determination of prognosis.13
The hematologic syndrome
The present paper emphasizes the hematologic subsyndrome 
based on the fact that growth factors have an important 
prophylactic effect on survival, provided that treatment 
is administered promptly.14–17 The earliest presentation of 
ARS is the hematologic syndrome. ARS may be observed 
in patients who receive whole-body doses ∼1 Gy, but gener-
ally it is not clinically significant at doses ∼2 Gy unless other 
combined injuries are present.9 The overlap of other organ 
damage with hematologic syndrome would be observed if 
patients survived long enough to manifest aplasia.5
Dose-dependent myelosuppression develops over 
1 week.2,3 Dose-dependent extramedullary toxicity also 
complicates management and increases mortality. Patients 
with radiation injury and burns or significant trauma have 
combined injury syndrome which is associated with a high 
mortality rate, even at lower radiation doses and with lesser 
bone marrow injury.3,4 In a mass casualty scenario, priority 
of treatment is based on the severity of patients’ condition, 
ie, the triage process, which sees radiation victims offered 
comfort care only.9,13 Granulocytes may transiently increase 
in patients with exposure of 5 Gy. This transient “abortive 
rise” before neutropenia may suggest a better prognosis.18
The nadir of neutrocytes can take 1–4 weeks to occur, 
with a longer time to nadir at lower doses (Table 3).2,4,18–20 
These patients are still exposed to high risk as the duration 
of neutropenia may be prolonged, requiring extended   support 
with hematopoietic growth factors, blood products, and 
antimicrobials. Patients with concomitant burns or traumatic 
injuries often show poor wound healing and bleeding, and 
without aggressive medical support, the mean lethal dose of 
radiation leads to 50% mortality at 60 days in a whole-body 
radiation dose of ∼3.5 Gy.3 This radiation dose increases to 
6–7 Gy with optimal supportive care, antimicrobials, and 
transfusion support.8,9,13,21
Survival requires hematologic 
recovery
Management of patients with ARS includes early use of 
hematopoietic cytokines, antimicrobials, and transfusion 
support. Recommendations based on radiation dose and 
physiologic response is made for treatment of the hema-
tologic syndrome, and therapy includes treatment with 
hematopoietic cytokines, blood transfusion, and, in selected 
cases, HCST.8,9,13
Additional medical management based on the evolution 
of clinical signs and symptoms includes the use of antimi-
crobial agents (quinolones, antiviral therapy, and antifungal 
agents), antiemetic agents, and analgesic agents. Because of 
the strong psychological impact of possible radiation expo-
sure, psychosocial support is required for those exposed, 
regardless of the dose.
The prevention and management of infection is the 
mainstay of therapy. There is a quantitative relationship 
between the degree of neutropenia and the increased risk of 
infectious complications.8,9 Antibiotic prophylaxis should 
only be considered in afebrile patients at the highest risk for 
infection. These patients have profound duration of more than 
7 days neutropenia (eg, measured in whole blood as absolute 
  neutrophil count ,500/mL). Although the degree of neu-
tropenia is the greatest risk factor for developing   infection, 
Table 3 Acute radiation syndrome imposes a critical hematopoietic 
response19,20
Hematopoietic  
outcome
Predictors
Reversibility Granulocytes: moderate granulocytosis, initial 
increase with a nadir between 4–10 days. Secondary 
increase day 20–30 
Lymphocytes: decline to nadir levels within 2 days, 
thereafter slow recovery 
Platelets: initial 10-day shoulder followed by decline 
toward day 20, nadir: days 20–30
Irreversibility Granulocytes: initial granulocytosis and progressive 
decline of cell counts between day 4 and day 6 
Lymphocytes: progressive decline within 24 hours 
Platelets: progressive decline within the first 10 days
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other factors influence treatment choice and outcome. Such 
factors include duration of neutropenia, bactericidal function-
ality of surviving neutrophils, alteration of physical defense 
barriers, the patient’s endogenous microflora, and organisms 
endemic to the hospital and community.19 As the duration of 
neutropenia increases, the risk of secondary infections such 
as invasive mycoses also increases.19
It is for these reasons that adjuvant therapy such as the 
cytokines sargramostim (GM-CSF [Leukine®; Immunex, 
Seattle, WA]) and filgrastim (G-CSF [Neupogen®; Amgen, 
Inc, Thousand Oaks, CA]) will prove invaluable in the 
treatment of the severely irradiated person, although only 
sparse data is available.8,9 The treatment recommendations 
on irradiation-associated aplasia are based on the known 
effect of CSF’s beneficial effect on recovery of neutrophils 
in oncology and hematology patients22–27 and in recipients 
of bone marrow transplantation,28–32 on their seemingly 
positive role on hematological recovery in a small number 
of radiation accident victims,7,14–17 and, most importantly, on 
the improved survival and positive effects on neutrophils 
in a number of well-conducted studies of animals exposed 
to radiation.33–42
Treatment with growth factors
Cytokines include GM-CSF, macrophage CSF, G-CSF, 
stem cell factor, and interleukin series (interleukin-1 to 
interleukin-16). GM-CSF and G-CSF have been available 
since 1997 for the treatment of radiation myelosuppression. 
G-CSF, also known as filgrastim, is administered in a dose 
of 100–200 mcg/m2/day and GM-CSF, also known as sargra-
mostim, is administered in a dose of 200–400 mcg/m2/day. 
Both are given intravenously or subcutaneously. Both drugs 
should be initiated promptly upon diagnosis of significant 
bone marrow damage and continued until recovery of neu-
trophil counts is sustained above 800/mm3.9
G-CSF and GM-CSF are currently in widespread clinical 
use for the treatment of acute neutropenic conditions, and 
in turn are used in the management of infections following 
radiochemotherapy of cancer patients. Both of these agents 
are potent but selective stimulators of granulopoietic arm 
of the hematologic system, and serve not only to increase 
blood neutrophil counts but also to enhance the maturation 
and function of these vital cells (Figure 1). Both agents 
have high therapeutic ratios, minimal nonperformance side 
adverse effects, can be administered and monitored with 
relative ease, and can effectively serve to minimize the 
risk of infection resulting from a radiation-compromised 
  lymphohematopoietic system.
G-CSF and GM-CSF are potent stimulators of hematopoi-
esis and effective in reducing duration and degree of 
  neutropenia. An additional benefit of CSFs is their ability 
to increase functional capacity of neutrophil and thereby 
contribute to the prevention of infection in an active role as 
cellular host. They constitute a remarkable advance in the 
treatment of neutropenia and are, thus, powerful tools for 
oncologists in the clinical management of cancer patients. 
The drugs act upon uncommitted stem cell populations within 
bone marrow to increase mitotic rate, accelerate repopulation, 
differentiate daughter cells to become committed stem cells, 
speed the maturation process, and improve the function of 
existing granulocytes (Figure 1). In this way, they improve 
the immune function of existing cells while speeding the 
recovery of stem cell populations, thus reducing the extent 
and duration of the white cell nadir and total compromise 
of the immune system.
Studies of cancer patients suffering from neutropenia 
consistently show that use of these cytokines reduces 
infection rates, admissions, and days hospitalized.23,25,27–29 
GM-CSF and G-CSF have both been used for treatment 
of ARS because their effect on granulocytes and myeloid 
stem cell lines do not come at the expense of other marrow 
cell lines. In order to achieve maximum clinical response, 
G-CSF or GM-CSF should be started as soon as possible after 
exposure.5–9,14 This provides the opportunity for maximum 
recovery. Cytokine administration should continue, with 
daily consecutive injections, to reach the desired effect of 
an absolute neutrophil count of 1000/µL after the absolute 
neutrophil count nadir (Table 4).
Biodosimetry
Individual biodosimetry is from a theoretical viewpoint 
essential for predicting subsequent clinical severity, morbid-
ity, and mortality. A range of clinical “dosimetric” utility 
has been developed for bedside use, such as several biologi-
cal indicators recently described.43–45 The method with the 
highest accuracy and considered the “gold standard”13 is the 
chromosomal aberration method, but the test usually takes 
3–5 days to develop (Table 5).46,47
Prompt treatment with growth 
factors in ARS
Prophylactic intervention
A number of papers document that a prompt initiation of 
treatment with growth factors implies an optimal outcome 
after radiation exposure,8,9 as the tissue macrophages will be 
transformed into fully matured immunocompetent dendritic 
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GM-CSF
Bone marrow Organs and tissues Circulation
GM-CSF
GM-CSF
Resting inactive
Immature and mature
Immunocompetent
Lymphocyte
Immature/Mature
Effect of GM-CSF via its
GM-CSF independent pathway
1 4
2
2
3
5
Figure 1 Systemic administration either by infusion or subcutaneous dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) activates the stem cells of 
neutrocytes and macrophages/monocytes. Consequently these cell lines maturate and proliferate (1). The circulating monocytes (2) become tissue macrophages, which 
are present in both bone marrow and peripheral organs including the lungs. The monocytes transform into tissue macrophages in tissue (3). After stimulation, GM-CSF 
receptors transform resting alveolar macrophages into immunocompetent dendritic cells corresponding to the autocrinic GM-CSF response locally (4), during which process 
both T-lymphocytes and granulocytes are being recruited from circulation (5). In acute radiation syndrome, cells in bone marrow and tissue macrophages stop participating 
in the host because the local GM-CSF is no longer expressed. As a consequence, host defense is reduced with a fatal lack of barriers against endogenous and exogenous 
microbiological agents, but the administration of GM-CSF via the subcutaneous/infusion route will normalize the host. However, macrophages in the lungs can only be 
reached by inhalation, the only way to upregulate and to protect the lung host.
Table 4   Comparison  of  granulocyte-macrophage  colony-stimulating  factor  (GM-CSF)  and  granulocyte  colony-stimulating  factor 
(G-CSF)14,22,23,37–39,41
GM-CSF G-CSF
Upregulatinga Effect on monocytes, tissue macrophages, and granulocytes Only effect on granulocytes
Adverse effects Fever, nausea, fatigue, headache, bone pain, myalgia Medullary bone pain observed shortly after 
initiation of G-CSF treatment
Dosing 200–400 mg/m2/day 5 µg/kg body weight
Initiation Promptly when significant 
radiation dose is suspected
Either promptly when significant radiation 
dose is suspected or when 
neutrocytes ,0.5 × 109
Stopping criteria Neutrocytes increasing, eg, .1.0 × 109 ANCb Neutrocytes increasing, eg, .1.0 × 109 ANC
Route of administration Subcutaneous/Infusion/Inhalation Subcutaneous/Infusion
Notes: aIncludes both quantitative (increased number) and qualitative (improved maturation and function) related variables effects; bstopping criteria should be based on the 
response of macrophage activation, however, this variable cannot be measured, therefore the stopping criteria of G-CSF is applied. 
Abbreviation: ANC, absolute neutrophil count.
cells in 7–10 days. This implies that preemptive interven-
tion, or intervention initiated as early as possible after the 
radiation exposure, is the preferred intervention after an 
exposure of a high radiation dose, eg, whole-body exposure 
to a radiation dose of 2–3 Gy, at which time the number and 
function of the peripheral monocytes and neutrocytes are 
not yet affected. Treatment of ARS with GM-CSF ensures 
both quantitative and qualitative effect on all effector cells, 
ie, monocytes, tissue-bound macrophages, and neutrocytes 
(Figure 1), as G-CSF does not stimulate local maturation of 
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Table 5 Comparison of dosimetric methods and their utility18,46,47
Dosimetry Methods Utility
Biological whole-body counting Not practical, generally 
not available
Chromosomal aberrations  
(dicentrics and ring forms)
The “gold standard,” 
however it takes 4–5 days 
processing time
Clinical Signs and symptoms In spite of high 
practicability, clinical 
dosimetry has low 
sensitivity particularly  
at low doses
resting and immunoincompetent macrophages. In organs and 
tissues, these cells will mediate their front defense bastion in 
relation to the immune defense. The activated macrophages 
orchestrate the overall actions and recruitment of systemic 
host cells like the lymphocytic cells and neutrophils, ensuring 
and maintaining a normal host barrier function in respect to 
endogenous and external biological agents in the hypoplastic 
or aplastic ARS patient. Macrophages are found in all human 
tissues, not only in bones, skin, and mucosa (eg, of the 
gut, eye, peritoneum, and meninges), but also in all organs 
including lungs, kidneys, heart, central nervous system, peri-
cardium, pleura, and liver. Only GM-CSF, and not C-CSF, 
activates macrophages by production from location-specific 
tissue cells. Therefore, in the sealed-off compartment of the 
lungs, activation of the macrophages can only be achieved 
by stimulation of GM-CSF, either by local production or by 
inhalation (Figure 2).
Local pulmonary host defense and ARS
There has recently been a discussion whether recombinant 
proteins should be inhaled or administered systemically in 
order to achieve a pulmonary effect by reaching the alveolar 
receptors.48 The question is then, which is the preferred route 
when intervening with GM-CSF?
In bone marrow, stem cells, and all organs, macrophage 
activity is enhanced by the systemic administration of 
GM-CSF dosing. In a radiation disaster, the lungs receive 
a comparable dose of radiation as the rest of the body, but 
as the lungs depend solely on local endogenous GM-CSF 
expression by alveolar macrophages, the endogenous GM-
CSF produced from systemic tissues does not penetrate across 
the alveolar capillary barrier.
It has been documented that inhaled GM-CSF increases the 
number and function of phagocytic cells from bronchoalveolar 
lavage, but only a sparse and transient increase in the number 
of myeloid cells in circulation.34 When administered intrave-
nously, however, there is only a limited response in alveolar 
  cellularity. It follows that pulmonary innate host defense is 
separated from the systemic defense system in respect to 
2
1
3
P
a  
b
P
AB
Y
Figure 2 (A) The lung is the most vulnerable vital organ when exposed to acute irradiation because of the “double hit” radiation exposure, ie, a combined exposure of 
inhaled particles (P) and from gamma radiation (γ) similar to the rest of the body (a). The lung host is dependent on its local granulocyte-macrophage colony-stimulating factor 
(GM-CSF) being expressed by alveolar cells. Intravenous or subcutaneous administration of GM-CSF does not reach its target in the alveolar space as it is “sealed off” from 
the airspace due to its water solubility and molecular size.34 In order to upregulate the pulmonary host by activating the resting alveolar macrophages (Figure 1), GM-CSF has 
to be inhaled. Due to radiation injury, the lung is accordingly exposed to severe dysfunction. GM-CSF does not penetrate the alveolocapillary membrane from “the blood 
side” to “the air side” or vice versa. (B) when GM-CSF is administered systemically (1), it “bypasses the alveolocapillary membrane” and via pulmonary circulation reaches 
the remaining tissues and organs (2). The only way to upregulate the pulmonary host is to inhale GM-CSF (3). 
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  GM-CSF, and that biologicsa does not penetrate from systemic 
circulation to the alveolar space.34 It has been documented that 
when administered intravenously, only 2% of smaller mole-
cules such as recombinant antitrypsin reach the alveolar space.49 
In larger molecules, such as recombinant activated protein C, 
there is no effect when administered intravenously,50 however 
when inhaled, activated protein C achieves the expected effect 
in the alveolus with no adverse effects.51,52
An important point is whether the inhaled drug reaches 
the GM-CSF receptors of alveolar macrophages in the periph-
eral airways. By using a micropump nebulizer, sufficiently 
small respirable aerosol particles with a size of ∼2.5 µm are 
produced which means that a high degree of peripheral lung 
deposition is obtained.53,54
It has been thoroughly documented that there are no known 
adverse effects in relation to administering inhaled GM-CSF, 
even when administered in very high doses.23,24,55–57
Inhaled GM-CSF in antiradiation 
intervention in ARS
Inhaled GM-CSF in antiradiation intervention maintains lung 
host defense and prevents severe pneumonia with endog-
enous microbiological agents such as viruses, bacteria, and 
fungi. Inhaled GM-CSF should be administered promptly and 
concomitantly with systemic intervention in the antiradia-
tion therapy regime. The initial dose should be ∼300 µg/day 
up to 300 µg/m2 daily depending on the response.9 The 
inhaled drug is effective and has no adverse effect even in 
the very high dose range, making it highly recommendable 
in ARS.7,9,14
Overall plan for care of irradiation 
victims
Management of the hematologic syndrome, as a component 
of acute radiation sickness, requires understanding of its 
manifestations and implementation of clinical biodosimetry 
to provide appropriate therapeutic support. Hematopoietic 
growth factors may be of value if administered early as a 
component of supportive care. Planning for urgent HSCT for 
those with intermediate- to high-dose radiation (4–10 Gy) 
may be required (Table 6),4,5,8,9,14,58 although the use of HSCT 
is controversial as outcomes after radiation accidents have 
been poor.59,60 Establishing contingency plans for triage, 
assessment, supportive care, and treatment with defined eli-
gibilities, treatment plans, and incorporated data collection 
to assess results and plan further improvements in care is 
imperative for the effective management of large scale radia-
tion accidents.13 The hematology/oncology community is 
most suited to participate in such contingency planning.21
Timing of treatment with growth 
factors
In the case of a nuclear event, it is likely that it would take 
many hours, if not days, to estimate the radiation exposure 
for each patient; thus, in any adult with an expected expo-
sure greater than 2 Gy, treatment with growth factors should 
be initiated as soon as biodosimetry results suggest that 
such an exposure has occurred or when clinical signs and 
symptoms indicate a serious level of hematotoxicity, while 
there may be initial granulocytosis followed by significant 
neutropenia.8,9 Growth factor treatment should be contin-
ued throughout this entire period in order to not overlook 
reversible aplasia, and as discussed in detail in this review, 
Table 6 Candidates for bone marrow transplantation8,9
First step 
Prompt growth factor intervention
 
In the case of aplasia in relation to acute radiation syndrome, emergency HSCT is not necessary. 
G-CSF/GM-CSF promotes hematological reconstruction and should be evaluated after prompt 
administration and after 14 days of high dose GM-CSF administration
Second step 
Final evaluation for candidates for HSCT
 
HSCT should only be implemented after residual hematopoiesis and only considered if severe  
aplasia persists after long G-CSF/GM-CSF high-dose treatment
Abbreviations:  G-CSF,  granulocyte  colony-stimulating  factor;  GM-CSF,  granulocyte-macrophage  colony-stimulating  factor;  HSCT,  hematopoietic  stem  cell 
transplantation.
Table 7 Treatment of acute radiation syndrome with growth 
factors, a proposed new preemptive treatment regime
Growth factor
Systemic therapy GM-CSF: s.c. or infusion 400 µg/m2a 
GM-CSF: s.c. or infusion 5 µg/kg
Local pulmonary GM-CSF: inhalation 400 µg per dayb
Notes: Growth factors should be administered promptly after radiation exposure 
by sufficient dosing to promote early hematological recovery. aSquare meter body 
surface;  bpreferably  use  micropump  nebulizer,  eg,  Aeroneb®  nebulizer  system 
(Aerogen Ltd, Galway, Ireland), as this type of nebulizer does not interfere with the 
active sites of the molecule. 
Abbreviations:  G-CSF,  granulocyte  colony-stimulating  factor;  GM-CSF, 
granulocyte-macrophage colony-stimulating factor; s.c., subcutaneously.
aA medicinal product, such as recombinant therapeutic proteins like 
  GM-CSF, that is produced by biologic processes.
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  recommendations should include both a systemically-
administered dose of growth factor G-CSF/GM-CSF and an 
inhaled dose of GM-CSF to ensure maximal response and 
protection from infection (Table 7).
Conclusion
Medical management of victims exposed to intentional or 
accidental radiation is complex and demands many resources. 
The primary responsibility for optimizing outcome resides 
with hospital staff, physicians, and healthcare facilities. 
Careful documentation of clinical signs and symptoms and 
estimation of individual radiation dose are required for medi-
cal triage. While loss of life in a nuclear detonation may be 
enormous, the survival benefit afforded those who receive 
modern supportive care is significant. Effective care requires 
implementation of a well-organized contingency plan for a 
scenario that takes into account loss of infrastructure.
Acute exposure to radiation induces a well-defined clini-
cal entity, the so-called ARS with four distinct phases. The 
main issue in ARS is to prevent radiation-induced organ 
dysfunction, where the most vulnerable cells and organs are 
the bone marrow hematopoietic cells and the fixed tissue and 
organ macrophages.
The main emphasis in early ARS phase is to prevent 
radiation-induced reduced host defense, where the main risk is 
aplasia and irreversible organ dysfunction. In order to increase 
the survival rate after radiation exposure, it is most important 
to prioritize hematologic recovery. The latest general standard 
intervention is prompt treatment with growth factors. The 
United States recommendation is growth factors (G-CSF/
GM-CSF) administered as an infusion/subcutaneous dose 
for the prevention of loss of host defense in ARS. A level of 
“high radiation exposure” is arbitrarily chosen in order to not 
overlook potential bone marrow aplasia, as it is impossible to 
predict how many victims would develop ARS with clinically 
significant pancytopenia after radiation exposure. However, an 
important issue here is the prevention of organ dysfunction. In 
ARS, organs of the host are driven by fixed tissue macrophages 
which, after stimulation with GM-CSF, will be transformed 
into immunocompetent dendritic cells, which in turn finally 
orchestrate the outer-barriers host against endogenous and 
exogenous microbiological agents. By the administration of 
growth factors (G-CSF/GM-CSF) systemically, however, the 
lung is specifically vulnerable to radioactive exposure as its 
host is isolated from the rest of the circulation system. The 
alveolocapillary membrane is sealed off from the systemic pool 
of drugs for protein-like-medicaments. Proteins are, however, 
soluble and too large to penetrate the membrane. A novel 
dual treatment regime after radiation exposure is therefore 
proposed. The treatment plan emphasizes the importance of 
prophylactic treatment with both systemically-administered 
G-CSF/GM-CSF and additional inhaled adequate doses of 
GM-CSF in order to ensure a hematologic response in the 
entire body, including the pulmonary system.
Ultimately HSCT should only be considered provided 
that bone marrow aplasia persists after 3 weeks treatment 
with high doses of GM-CSF without any response in the 
neutrocyte count, ie, with no residual hematopoiesis.
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